OCULAR IMPLANT MARKET ANALYSIS

Market News

Increasing number of product launches are expected to drive growth of the global ocular implants market. For instance, in July 2018, Alcon, an ophthalmology company had launched its intraocular lens (IOL) portfolio including, Clareon AutonoMe IOL and delivery system, designed to provide easy and intuitive control during cataract surgery, at the Alcon-hosted Synergeyes clinical symposium in Sydney. AutonoMe is the first and only automated, disposable, preloaded IOL delivery system preloaded with the Clareon IOL, and it is automated with CO2-powered delivery mechanism. Moreover, in June 2018, Molteno Ophthalmic, medical device company launched its Molteno3 S-Series glaucoma implants at the 24th Greek Glaucoma.

Global Ocular Implant Market: Key Developments

In June 2022, EyePoint Pharmaceuticals, Inc., pSivida, Pharmaceutical Company, received Chinese regulatory body approval for an implant to treat a form of eye inflammation, becoming the first company to get a nod in the country based entirely on real-world data. Ocumension Therapeutics paid an initial $1.75 million to access EyePoint’s technology in 2018. Ocumension Therapeutics filed for National Medical Products Administration (NMPA) approval of Yutiq in April 2021. According to the biotech, the filing was the first submission for National Medical Products Administration approval of a sustained-release micro-insert with a controlled release rate of up to 36 months and the first time The positive National Medical Products Administration decision triggered a further claim, namely that Yutiq is the first medicine approved in China based entirely on real-world data. The Chinese regulator had accepted a new drug application based on real-world study data.

Increasing prevalence of corneal diseases is expected to increase demand for ocular implants.